https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-02-01 / J. Immunother. 2010 Feb-Mar;33(2):155-66
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-02-01 / J. Immunother. 2010 Feb-Mar;33(2):155-662010-02-01 00:00:002019-02-15 08:44:00Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-30 / Cell Adh Migr 2010 Jan-Mar;4(1):153-61
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-30 / Cell Adh Migr 2010 Jan-Mar;4(1):153-612010-01-30 00:00:002019-02-15 08:50:36What’s the place of immunotherapy in malignant mesothelioma treatments?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-29 / Curr. Opin. Immunol. 2010 Feb;22(1):137-44
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-29 / Curr. Opin. Immunol. 2010 Feb;22(1):137-442010-01-29 00:00:002019-02-15 08:44:07Presentation of tumour antigens by dendritic cells and challenges faced
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-06 / BMC Cancer 2010 Jan;10:5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-06 / BMC Cancer 2010 Jan;10:52010-01-06 00:00:002019-02-15 08:43:59Tocotrienols are good adjuvants for developing cancer vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / Crit. Rev. Immunol. 2010;30(4):345-86
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / Crit. Rev. Immunol. 2010;30(4):345-862010-01-01 00:00:002019-02-15 08:40:16Tumor antigen presentation by dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / Hum. Immunol. 2010 Jan;71(1):67-73
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / Hum. Immunol. 2010 Jan;71(1):67-732010-01-01 00:00:002019-02-15 08:44:09Identification of a microRNA signature in dendritic cell vaccines for cancer immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / Neurosurg. Clin. N. Am. 2010 Jan;21(1):111-23
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / Neurosurg. Clin. N. Am. 2010 Jan;21(1):111-232010-01-01 00:00:002019-02-15 08:48:31Heat shock proteins in glioblastomas
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / Methods Mol. Biol. 2010;595:149-63
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / Methods Mol. Biol. 2010;595:149-632010-01-01 00:00:002019-02-15 08:44:11Towards a standardized protocol for the generation of monocyte-derived dendritic cell vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / Immunotherapy 2010 Jan;2(1):57-68
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / Immunotherapy 2010 Jan;2(1):57-682010-01-01 00:00:002019-02-15 08:45:16Personalized dendritic cell-based tumor immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-01-01 / Neurosurg. Clin. N. Am. 2010 Jan;21(1):95-109
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-01-01 / Neurosurg. Clin. N. Am. 2010 Jan;21(1):95-1092010-01-01 00:00:002019-02-15 08:47:25Clinical applications of a peptide-based vaccine for glioblastoma
